Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nanjing Legend Bio Completes $424 Million NASDAQ IPO; Shares Rise 60%

publication date: Jun 5, 2020

In a very successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60 in early trading, giving Legend a market capitalization of nearly $5 billion. In 2017, Legend announced its anti-BCMA CAR-T therapy produced a 94% overall response rate in myeloma patients. Six months later, Janssen formed a 50-50 partnership with the company for the CAR-T candidate in a $1 billion-plus deal, including $350 million upfront. More details....

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.